| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.9 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.008 | 0.9 |